Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled, Double-blind, Multicenter, Phase III Clinical Study to Compare Efficacy and Safety of Abivertinib Maleate Versus First-line Standard Therapy EGFR-TKI in Patients With Advanced NSCLC With Sensitive EGFR Mutation

NCT03856697 is registered in ClinicalTrials.gov with Hangzhou ACEA Pharmaceutical Research Co., Ltd. as lead sponsor.

NCT NCT03856697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03856697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled, Double-blind, Multicenter, Phase III Clinical Study to Compare Efficacy and Safety of Abivertinib Maleate Versus First-line Standard Therapy EGFR-TKI in Patients With Advanced NSCLC With Sensitive EGFR Mutation
Lead sponsor
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
March 31, 2019
Completion date
March 31, 2024
Enrollment
406 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer